✨ Free AI Report
Immunome, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Immunome, Inc.
Company Research

Immunome, Inc.: Business Overview, Financials & Competitive Analysis

Immunome, Inc. scores 6/10 on the AskCyborg Cyborg Score (Solid). Immunome represents a clinical-stage oncology platform with validated Phase 3 data and multi-asset portfolio pursuing high-value cancer indications, though success depends on regulatory approvals and clinical advancement. The company delivered top-line Phase 3 results for Varegacestat in desmoid tumors and is in the process of filing a New Drug Application.

What is Immunome, Inc.'s industry? Immunome, Inc. (immunome.com) operates in Biopharmaceuticals - Targeted Oncology/Immunotherapy. AskCyborg classifies Immunome, Inc. under Biopharmaceuticals - Targeted Oncology/Immunotherapy in its company registry.

Immunome, Inc., a clinical-stage biotechnology company, develops targeted cancer therapies. The company is advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in t...

6/ 10Solid

Cyborg Score thesis

Immunome represents a clinical-stage oncology platform with validated Phase 3 data and multi-asset portfolio pursuing high-value...

Read the full analyst-debate transcript →
Industry Biopharmaceuticals - Targeted Oncology/Immunotherapy
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Immunome, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Immunome, Inc.

AskCyborg analysts argue the bull and bear cases for Immunome, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Immunome, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Immunome, Inc. Overview

Pro stress-test →

Immunome, Inc., a clinical-stage biotechnology company, develops targeted cancer therapies. The company is advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). With recent Phase 3 positive results and expanding pipeline, Immunome is positioned as a promising oncology-focused biotech targeting multiple cancer indications.

Strategic Profile

Pro stress-test →

Immunome is a clinical-stage biotechnology company focused on discovering and developing first-in-class targeted therapies for oncology, primarily using antibody-drug conjugate (ADC) technology, leveraging a proprietary, memory B cell-based discovery engine to identify novel antibodies that treat cancers. The company's strategy is centered on cell-surface-targeting agents and small molecules, with the ultimate goal to develop a targeted oncology platform that can overcome resistance and enable bystander activity.

Competitive Landscape

Pro stress-test →

Immunome competes in the targeted oncology and ADC therapeutics space against established biotech and pharma competitors developing cancer therapies. Key competitive differentiators include the company's proprietary memory B cell-based discovery engine, validated Phase 3 clinical data, and multi-asset pipeline focusing on cell-surface-targeting and radiotherapy approaches.

Industry Context

Immunome, Inc. operates in Biopharmaceuticals - Targeted Oncology/Immunotherapy.

Key facts

Founded: 2006 · Headquarters: Bothell, Washington · Market cap: $2.45B

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Immunome, Inc..

  • Phase 3 positive results for Varegacestat in desmoid tumors with NDA filing underway, targeting a $1 billion market opportunity and plans to submit three additional INDs this year for solid tumor programs.
  • Company's radioligand therapy (IM-3050) receives FDA clearance and is poised to start clinical trials.
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Immunome grants 30,000 inducement stock options to new employee at $26.14 exercise price
  • December 2025Announced positive topline Phase 3 results from RINGSIDE trial of Varegacestat in desmoid tumors
  • +2 moreTrack every material event for Immunome, Inc. as it happens. Explore monitoring →
Get alerted when Immunome, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Antibody-Drug Conjugate TherapiesEstablished ADC developers with marketed or late-stage programs→Gamma Secretase InhibitorsCompanies developing alternative desmoid tumor and cancer therapeutics→Radioligand TherapiesCompetitors in targeted radiation therapy space→

Compare Immunome, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Immunome, Inc. operates in Biopharmaceuticals - Targeted Oncology/Immunotherapy. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceuticals - Targeted Oncology/Immunotherapy research →
NEW · MCP server

Ask your AI assistant about Immunome, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Immunome, Inc. and its top competitor on Cyborg Score”
“What did Immunome, Inc. do this quarter?”
“Is Immunome, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Immunome, Inc. do?+
Immunome, Inc., a clinical-stage biotechnology company, develops targeted cancer therapies. The company is advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in t...
What is Immunome, Inc.'s Cyborg Score?+
Immunome, Inc. has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Immunome, Inc.'s main competitors?+
Named competitors include Antibody-Drug Conjugate Therapies, Gamma Secretase Inhibitors, Radioligand Therapies. The full competitive landscape is in the AskCyborg report.
How can I get the full Immunome, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Immunome, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Immunome, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.